Accueil   Diary - News   All news Advanced BioDesign publishes its study in non-small cell lung cancer (NSCLC) in Oncogene

Advanced BioDesign publishes its study in non-small cell lung cancer (NSCLC) in Oncogene

 

Study shows for first time benefit of its active compound DIMATE
in overcoming drug resistance in NSCLC

 

 

Lyon, France, May 12, 2020 – Advanced BioDesign, dedicated to developing novel therapies against resistant cancers, today announces promising results using its dual inhibitor DIMATE against an original therapeutic target, the ALDH enzymes family, in pulmonary cancer. The results, recently published in Oncogene, demonstrate that in lung cancer xenografts with high to moderate cisplatin resistance, a combination treatment with DIMATE promotes strong synergistic responses with tumor regression.

 

In support of these findings, the study highlights a new mechanism of action associated with the therapeutic target: the ALDH enzymes, notably ALDH1A3 and ALDH3A1. High expression of these enzymes confers an aggressive, chemoresistant behavior in non-small cell lung cancer (NSCLC) and reduces patient survival. This strongly suggests that ALDH1A3 and ALDH3A1 make cancer cells resistant to chemotherapy by disposing of their toxic compounds induced by chemotherapy, such as aldehydes and reactive oxygen species (ROS). A combination of DIMATE together with ROS-inducing agents, such as cisplatin, triggers a potent anti-tumor response at lower doses of chemotherapy, which also results in fewer side-effects.

 

 

 

Read the press release